The IV STING agonist, TAK-676, enhances immune-mediated anti-tumor activity of radiation in syngeneic mouse models

被引：0
|
作者：
Appleman, Vicky A. [1 ]
Berger, Allison J. [1 ]
Roberts, Emily R. [1 ]
Maldonado-Lopez, Angel E. [1 ]
Ganno, Michelle L. [1 ]
Christensen, Camilla I. [1 ]
Hatten, Tiquella [1 ]
Sato, Yosuke [1 ]
Shaw, Michael H. [1 ]
Malek, Karim S. [1 ]
Lineberry, Neil B. [1 ]
Abu-Yousif, Adnan O. [1 ]
Gregory, Richard C. [1 ]
机构：
[1] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3448
引用
收藏
页数：1
相关论文
共 47 条
  • [21] TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation
    Ota, Yosuke
    Inagaki, Ryosaku
    Nagai, Yasuhiro
    Hirose, Yuko
    Murata, Masashi
    Yamamoto, Setsuko
    BMC IMMUNOLOGY, 2024, 25 (01)
  • [22] A half-life extended, tumor-activated IL-12 increased the infiltration of effector immune cells into the tumor microenvironment and demonstrated anti-tumor activity in syngeneic mouse models
    Malkova, Natalia
    Patel, Ekta
    Vu, Sallyann
    Fantini, Damiano
    O'Donnell, Rebekah
    Fanny, Manoussa
    Greene, Justin
    Guzman, Wilson
    Crowe, David
    Hsiao, Stephanie
    Johnson, Parker
    McLaughlin, Megan
    Yerov, Oleg
    Jenkins, Kurt
    Halpin-Veszeleiova, Katarina
    Madala, Hanumantha Rao
    O'Toole, Caitlin
    Taylor, Jake
    Pederzoli-Ribeil, Magali
    Nicholson, Benjamin
    Bialucha, Carl Uli
    O'Neil, Jennifer E.
    CANCER RESEARCH, 2023, 83 (07)
  • [23] TUMOR CELL-INTRINSIC STING PATHWAY IS ACTIVATED IN THE PRESENCE OF CUES FROM IMMUNE CELLS AND CONTRIBUTES TO THE ANTI-TUMOR ACTIVITY OF TUMOR CELL-TARGETED STING AGONIST ANTIBODY-DRUG CONJUGATES
    Cetinbas, Naniye Malli
    Monnell, Travis
    Lee, Winnie
    Catcott, Kalli
    Chin, Chen-Ni
    Shaw, Pamela
    Slocum, Kelly
    Qin, LiuLiang
    Avocetien, Kenneth
    Bentley, Keith
    Clardy, Susan
    Jones, Brian
    Kelleher, Eugene
    Thomas, Joshua
    Mosher, Rebecca
    Toader, Dorin
    Duvall, Jeremy
    Bukhalid, Raghida
    Damelin, Marc
    Lowinger, Timothy
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A373 - A373
  • [24] AAV-mediated expression of mouse IL-12 shows potent anti-tumor activity through innate immunological activation in syngeneic murine cancer models
    Fellner, D.
    Prentiss, P.
    Liu, J.
    Stone, M.
    Stone, M.
    Roeloffs, R.
    Furmanski, B.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A186 - A186
  • [25] Discovery of highly potent, selective, and orally bioavailable IKZF2 degrader and its anti-tumor activity in syngeneic mouse models
    Park, Seulki
    Moon, Jeong Hee
    Lee, Gaseul
    Kim, Hyun Jin
    Kim, Jeong-Hoon
    Hwang, Jong Yeon
    CANCER RESEARCH, 2024, 84 (06)
  • [26] Pharmacologic inhibition of HPK1 kinase activity enhances immune cell activation and T cell mediated anti-tumor activity
    Lee, Jacob S.
    Toy, Pamela
    Min-Oo, Gundula
    Lee, Tony
    Salvo, Patrick
    Belzile, JeanPhilippe
    Clancy, Sheila
    Nazareno, Jonathan
    Xu, Mengshu
    Xing, Weimei
    Giacomini, Marilyn
    Santos, Rex
    Stapleton, Lance
    Wang, Adele
    Juric, Vladislava
    Mitchell, Scott A.
    Kuhne, Michelle
    CANCER RESEARCH, 2022, 82 (12)
  • [27] Inhibition of integrin αvβ8 enhances immune checkpoint induced anti-tumor immunity by acting across immunologic synapse in syngeneic models of breast cancer
    Reszka-Blanco, Natalia J.
    Yadav, Vinod
    Krumpoch, Megan
    Cappellucci, Laura
    Cui, Dan
    Dowling, James E.
    Gwara, Elizabeth
    Harrison, Bryce
    Lee, Dooyoung
    Lin, Fu-Yang
    Luus, Lia
    Monroy, Meghan
    Moy, Terence I.
    Nebelitsky, Eugene
    Qiao, Qi
    Sullivan, Andrew
    Troast, Dawn
    Lippa, Blaise
    Rogers, Bruce
    Ray, Adrian S.
    CANCER RESEARCH, 2021, 81 (13)
  • [28] WTX-613, A CONDITIONALLY ACTIVATED IFNα INDUKINE™ MOLECULE, INDUCES ANTI-TUMOR IMMUNE RESPONSES RESULTING IN STRONG TUMOR GROWTH CONTROL IN SYNGENEIC MOUSE TUMOR MODELS
    Tyagi, Ethika
    Brodkin, Heather
    Canales, Josue
    Hicklin, Dan
    Ismail, Nesreen
    Morris, Kristin
    Nirschl, Christopher
    Salmeron, Andres
    Seidel-Dugan, Cindy
    Steiner, Philipp
    Steuert, Zoe
    Sullivan, Jenna
    Winston, William
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A752 - A752
  • [29] Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models
    Li, Yanxia
    Amaladas, Nelusha
    O'Mahony, Marguerita
    Manro, Jason R.
    Inigo, Ivan
    Li, Qi
    Rasmussen, Erik R.
    Brahmachary, Manisha
    Doman, Thompson N.
    Hall, Gerald
    Kalos, Michael
    Novosiadly, Ruslan
    Puig, Oscar
    Pytowski, Bronislaw
    Schaer, David A.
    PLOS ONE, 2022, 17 (07):
  • [30] The tyrosine kinase inhibitor XL092 promotes an immune-permissive tumor microenvironment and enhances the anti-tumor activity of immune checkpoint inhibitors in preclinical models
    Hsu, Jeff
    Chong, Colin
    Serrill, Jeffrey
    Wu, Sharon
    Leong, Kevin
    Yun, Ted
    Bannen, Lynne
    Lamb, Peter
    Xu, Wei
    Yu, Peiwen
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
12345